|
|
 Previous Article | Table of Contents | Next Article 
Dilazep, an Antiplatelet Agent, Inhibits Tissue Factor Expression in Endothelial Cells and Monocytes
Hiroshi Deguchi,
Hiroyuki Takeya,
Hideo Wada,
Esteban C. Gabazza,
Nobuyuki Hayashi,
Hajime Urano, and
Koji Suzuki
From the Department of Molecular Pathobiology and the Second Department of Internal Medicine, Mie University School of Medicine, Tsu-city, Mie, Japan.
Dilazep, an antiplatelet agent, is generally used as an antithrombotic drug in clinical practice. Dilazep is also known to exert cytoprotective and antioxidant effects on endothelial cells. However, its effect on the endothelial or monocyte procoagulant activity is unknown. In the current study, the effect of dilazep on the expression of tissue factor (TF ) in human umbilical vein endothelial cells (HUVECs) after the stimulation with tumor necrosis factor- (TNF ), thrombin, or phorbol 12-myristate 13-acetate (PMA) was evaluated. We also evaluated the effect of dilazep on TNF (1,000 U/mL)-induced TF expression on monocytes. Dilazep inhibited TF activity induced on HUVECs by each stimulant, TNF (1000 U/mL), thrombin (25 nmol/L), or PMA (5 nmol/L) in a dose-dependent fashion (1 to 100 µg/mL). TF activity decreased to approximately 10% after treating with 100 µg/mL of dilazep. Dilazep also blocked the expression of TF antigen induced by each stimulant on the surface of HUVECs as determined by flow cytometric analysis. In addition, in HUVECs, it significantly decreased the expression of TF mRNA and the total TF antigen induced by thrombin or PMA, but not those induced by TNF, suggesting that dilazep blocks the TF expression induced by PMA or thrombin at a transcriptional level and that induced by TNF at a posttranscriptional level. Western blot analysis showed that dilazep reduces the accumulation of native TF but increases that in lower molecular weight TF derivatives. The adenosine receptor antagonist, 8-(p-sulfophenyl) theophylline, partially counteracted the anticoagulant activity of dilazep on HUVECs, thereby suggesting that the inhibitory effect of dilazep on TF expression in HUVECs depends, at least in part, on its adenosine potentiating activity. Dilazep also inhibited TNF-induced TF expression on monocytes in a dose-dependent fashion (0.1 to 100 µg/mL). In brief, the current study showed for the first time that dilazep, a commonly used antiplatelet drug, strongly inhibits the TF expression in HUVECs and monocytes. Dilazep may have a potent therapeutic value in patients with hypercoagulable state for its inhibitory property on the procoagulant activity of endothelial cells and monocytes.
Blood, Vol. 90 No. 6 (September 15), 1997:
pp. 2345-2356
© 1997 by The American Society of Hematology.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
X. V. Yang, Y. Banerjee, J. A. Fernandez, H. Deguchi, X. Xu, L. O. Mosnier, Rolf. T. Urbanus, P. G. de Groot, T. C. White-Adams, O. J. T. McCarty, et al.
Activated protein C ligation of ApoER2 (LRP8) causes Dab1-dependent signaling in U937 cells
PNAS,
January 6, 2009;
106(1):
274 - 279.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Kinev and R. Roubey
Tissue factor in the antiphospholipid syndrome
Lupus,
October 1, 2008;
17(10):
953 - 959.
[Abstract]
[PDF]
|
|
|
|
|
|
|
C. Lopez-Pedrera, P Buendia, M A Aguirre, F Velasco, and M J Cuadrado
Antiphospholipid syndrome and tissue factor: a thrombotic couple
Lupus,
March 1, 2006;
15(3):
161 - 166.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. Steffel, R. A. Latini, A. Akhmedov, D. Zimmermann, P. Zimmerling, T. F. Luscher, and F. C. Tanner
Rapamycin, but Not FK-506, Increases Endothelial Tissue Factor Expression: Implications for Drug-Eluting Stent Design
Circulation,
September 27, 2005;
112(13):
2002 - 2011.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Sakamoto, T. Ishibashi, N. Sakamoto, K. Sugimoto, K. Egashira, H. Ohkawara, K. Nagata, K. Yokoyama, M. Kamioka, T. Ichiki, et al.
Endogenous NO Blockade Enhances Tissue Factor Expression via Increased Ca2+ Influx Through MCP-1 in Endothelial Cells by Monocyte Adhesion
Arterioscler. Thromb. Vasc. Biol.,
September 1, 2005;
25(9):
2005 - 2011.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Zhou, A. S. Wolberg, and R. A. S. Roubey
Characterization of monocyte tissue factor activity induced by IgG antiphospholipid antibodies and inhibition by dilazep
Blood,
October 15, 2004;
104(8):
2353 - 2358.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Takeya, E. C. Gabazza, S. Aoki, H. Ueno, and K. Suzuki
Synergistic effect of sphingosine 1-phosphate on thrombin-induced tissue factor expression in endothelial cells
Blood,
September 1, 2003;
102(5):
1693 - 1700.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Nakamura, C. Ushiyama, K. Hirokawa, S. Osada, T. Inoue, N. Shimada, and H. Koide
Effect of cerivastatin on proteinuria and urinary podocytes in patients with chronic glomerulonephritis
Nephrol. Dial. Transplant.,
May 1, 2002;
17(5):
798 - 802.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Hoshi, M. Goto, N. Koyama, K.-i. Nomoto, and H. Tanaka
Regulation of Vascular Smooth Muscle Cell Proliferation by Nuclear Factor-kappa B and Its Inhibitor, I-kappa B
J. Biol. Chem.,
January 14, 2000;
275(2):
883 - 889.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Engelmann, S. Zieseniss, K. Brand, S. Page, A. Lentschat, A. J. Ulmer, and E. Gerlach
Tissue Factor Expression of Human Monocytes Is Suppressed by Lysophosphatidylcholine
Arterioscler. Thromb. Vasc. Biol.,
January 1, 1999;
19(1):
47 - 53.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
